Lanreotide Protocol: Complete Cycling & Dosing Guide
DISCLAIMER: This guide is educational content for informational purposes only and does not constitute medical advice. Lanreotide is a prescription medication requiring physician supervision. Use only under medical direction. This protocol information should not replace consultation with a qualified healthcare provider, endocrinologist, or specialist experienced in somatostatin analog therapy.
Overview
Lanreotide (Somatuline Depot) is a synthetic somatostatin analog administered as a deep subcutaneous injection with sustained-release properties lasting approximately 4 weeks. It functions as a G-protein coupled receptor agonist, binding with high affinity to somatostatin receptors (SSTR2 and SSTR5) to suppress growth hormone, IGF-1, insulin, glucagon, and gastrointestinal hormone secretion.
The clinical evidence base for lanreotide is strongest for hormonal control in acromegaly and tumor management in gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Cardiovascular improvements in acromegalic patients represent the most robust secondary benefit. The compound is not evidence-based for fat loss, joint health, general inflammation, sleep, energy, or longevity as standalone therapeutic goals.
Lanreotide is available exclusively as a prescription medication. Typical monthly costs range from $4,500 to $12,000, though insurance coverage and patient assistance programs may reduce out-of-pocket expenses significantly.
Standard Protocol
Dosing Range
Standard therapeutic dose: 60–120 mg administered via deep subcutaneous injection every 28 days (4 weeks)
- Starting dose: 60 mg every 4 weeks
- Maintenance dose: 60–120 mg every 4 weeks depending on clinical response
- Dose adjustment: Increases of 30–60 mg may occur based on hormone levels (IGF-1, growth hormone) or tumor marker response
Administration Frequency
Lanreotide Autogel is formulated for once-every-4-weeks administration. This extended interval results from the depot formulation's sustained-release kinetics, providing continuous drug delivery over the dosing period.
Do not attempt more frequent dosing (e.g., weekly or biweekly) unless under explicit physician direction, as the formulation is not designed for shorter intervals and may result in subtherapeutic or supratherapeutic exposure.
Injection Site Rotation
Rotate injection sites among the following locations to minimize local adverse effects:
- Upper outer quadrant of gluteal region (preferred)
- Abdomen (lateral or periumbilical)
- Upper arm (triceps region)
Allow at least 1–2 inches between injection sites and avoid sites with visible irritation, induration, or nodules. Document injection location to facilitate systematic rotation.
Storage
- Store lanreotide in a refrigerator at 36–46°F (2–8°C) prior to administration
- Protect from light
- Do not freeze
- Allow to reach room temperature (68–77°F) for approximately 30 minutes before injection if desired to reduce injection site discomfort
- Once reconstituted or prepared for injection, administer within the timeframe specified by the manufacturer (typically same day)
Monitoring Parameters
Baseline and ongoing monitoring should include:
| Parameter | Frequency | Notes |
|---|---|---|
| IGF-1 and growth hormone | 4 weeks after initiation, then every 8–12 weeks | Target normalization of IGF-1 for acromegaly |
| Fasting glucose | Baseline, 4 weeks, then every 12 weeks | Risk of hyperglycemia and glucose dysregulation |
| Liver function tests | Baseline, 4 weeks, then every 12 weeks | Assess hepatic tolerance |
| Abdominal ultrasound or imaging | Baseline, 6 months, then annually | Screen for cholelithiasis |
| Cardiac function (echocardiography) | Baseline, 6 months if acromegaly present | Assess for cardiac improvements or conduction abnormalities |
| Heart rate and blood pressure | Every 4 weeks | Monitor for bradycardia |
| Injection site assessment | Every 4 weeks | Evaluate for nodules, induration, or persistent pain |
Goal-Specific Protocols
Protocol A: Acromegaly Management (Hormonal Control)
Duration: Indefinite; maintenance therapy required
Dosing cycle:
- Weeks 1–4: 60 mg IM deep subcutaneous injection, day 1
- Weeks 5–8: 60 mg IM deep subcutaneous injection, day 1 (repeat)
- Adjust to 90 mg or 120 mg every 4 weeks if IGF-1 remains elevated after 8–12 weeks
Expected timeline:
- Days 1–7: Gradual decline in growth hormone and IGF-1
- Weeks 2–4: Plateau of suppressive effect
- Weeks 4–8: Assessment period; IGF-1 levels typically normalize by 8–12 weeks if dose is adequate
Signs of adequacy:
- IGF-1 normalization (age-matched reference range)
- Growth hormone suppression to <2 ng/mL in fasting state
- Symptom improvement (reduced joint pain, improved grip strength, decreased soft tissue swelling)
Adjustment criteria:
- If IGF-1 remains elevated at 12 weeks, increase dose to 90 mg every 4 weeks
- If still elevated at 8–12 weeks on 90 mg, escalate to 120 mg every 4 weeks
- Doses above 120 mg are not standard and require specialist input
Protocol B: Neuroendocrine Tumor Management (GEP-NETs)
Duration: Long-term; typically 24+ months based on progression-free survival data
Dosing cycle:
- Weeks 1–4: 60–90 mg IM deep subcutaneous injection, day 1
- Weeks 5–8: Same dose (repeat every 4 weeks)
- Adjust based on tumor marker response (chromogranin A, 5-HIAA, pancreatic polypeptide depending on tumor type) and imaging-based progression assessment
Expected timeline:
- Days 1–14: Initial reduction in hormone/peptide secretion; symptom relief in carcinoid syndrome
- Weeks 4–12: Stabilization of tumor biomarkers
- Months 3–6: Imaging reassessment to confirm antiproliferative effect
Signs of efficacy:
- Reduction in tumor biomarkers (chromogranin A, 5-HIAA)
- Symptom control (reduced diarrhea in carcinoid, reduced flushing)
- Radiographic stability (no growth on CT/MRI)
Adjustment criteria:
- If progression on initial dose, increase to next available dose (60→90→120 mg)
- If toxicity is limiting, dose reduction or extended intervals (every 5–6 weeks) may be considered under specialist guidance
- Continue indefinitely unless disease progression mandates chemotherapy or alternative intervention
How to Administer Step-by-Step
Pre-Injection Checklist
- Verify prescription and dose with your pharmacist or healthcare provider
- Remove lanreotide from refrigerator 30 minutes before injection to allow warming to room temperature
- Inspect the vial or syringe for discoloration, particles, or cloudiness; do not use if compromised
- Assemble supplies: Sterile alcohol wipe, sterile gauze, adhesive bandage, sterile 1–1.5 inch needle (typically 25–27 gauge, provided in kit)
- Select and mark injection site using systematic rotation (avoid recent injection sites with visible irritation)
Injection Technique
- Clean the injection site with an alcohol wipe using a circular motion; allow 30 seconds to air-dry completely
- Pinch the skin to create a skin fold at the injection site
- Hold the syringe at a 45–90 degree angle to the skin surface (perpendicular preferred for consistency)
- Insert the needle in one smooth, swift motion through the skin into the subcutaneous tissue
- Release the skin fold once the needle is fully inserted (do not reinsert)
- Inject slowly over 5–10 seconds to allow full distribution into the depot layer
- Withdraw the needle at the same angle of insertion
- Apply gentle pressure with sterile gauze for 30–60 seconds
- Apply adhesive bandage and document the injection (date, site, dose, time)
Post-Injection Care
- Observe for excessive bleeding or signs of vascular puncture (rare)
- Expect mild injection site discomfort, erythema, or mild induration for 24–48 hours
- Avoid vigorous activity or massage of the injection site for 24 hours
- Apply ice if significant swelling or pain develops